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Abstract
A large body of evidence demonstrates that angiotensin II and angiotensin receptors are required
for the pathogenesis of experimental lung fibrosis. Angiotensin has a number of profibrotic effects
on lung parenchymal cells that include the induction of growth factors for mesenchymal cells,
extracellular matrix molecules, cytokines and increased motility of lung fibroblasts. Angiotensin is
also proapoptotic for lung epithelial cells, and is synthesized by a local system (i.e. entirely within
the lung tissue) after lung injury by a variety of agents of both xenobiotic and endogenous origins.
Recent evidence shows that the counterregulatory molecule angiotensin 1-7, the product of the
enzyme ACE-2, inhibits epithelial cell apoptosis and thus acts as an antifibrotic epithelial survival
factor. This manuscript reviews the evidence supporting a role for angiotensin in lung fibrogenesis
and discusses the signalling mechanisms underlying its action on lung parenchymal cells
important in the pathogenesis of pulmonary fibrosis.
In vivo evidence implicating ANGII in lung fibrogenesis
Pulmonary fibrosis results from injury to the lung and an ensuing fibrotic response that leads
to thickening of the alveolar walls and the obliteration of alveolar air spaces. If the etiology
is unknown, the condition is designated as idiopathic pulmonary fibrosis (IPF) [1]. There are
also various chemical toxins and other injuries known to cause pulmonary fibrosis, for
example the antineoplastic agent bleomycin, the antiarrhythmic agent amiodarone, radiation,
silicon dust and asbestos [2]. The main histological features of the fibrotic lung are
persistent and unrepaired epithelial damage, proliferation and accumulation of fibroblasts
and myofibroblasts, and increased collagen deposition [3]. This section will discuss in vivo
evidence implicating ANGII in lung fibrogenesis.
The angiotensin system consists of angiotensinogen (AGT), an aspartyl protease such as
renin or cathepsin D, angiotensin-converting enzyme (ACE), angiotensin II (ANGII) and
angiotensin II type 1 and type 2 receptors (AT1, AT2). A recently discovered
counterregulatory axis is composed of ACE-2, its product angiotensin 1-7 (ANG1-7) and the
ANG1-7 receptor mas [4, 5]. There is significant in vivo evidence suggesting that the
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angiotensin system is involved in pulmonary fibrosis. The evidence includes genetic studies
of ANG system gene polymorphisms in patients with lung fibrosis, demonstrations of
activated ANG system genes and protein products in lung biopsy specimens from patients
with lung fibrosis and a variety of animal model studies. The next section however, will
discuss only the data from animal models.
In a variety of animal models, angiotensin system antagonists block experimental lung
fibrosis. There is a substantial body of in vivo studies which demonstrated that ANGII plays
a very important role in lung fibrogensis by blocking ANGII synthesis or its functions.
Recently, we demonstrated that coadministration of antisense oligonucleotides against AGT
mRNA, by blockade of the synthesis of lung-derived AGT, prevents bleomycin-induced
lung cell apoptosis and lung fibrogenesis [6]. Furthermore, application of ACE inhibitors to
inhibit ANGII production has been shown to attenuate experimental pulmonary fibrosis in
animal models induced by various agents. For example, the ACE inhibitors Captopril [7],
Enalapril [8], Lisinopril [9] and Perindopril [10] exerted inhibitory effects on bleomycin-, γ
irradiation-, amiodarone- and paraquat- induced pulmonary fibrosis in rats, and on
hyperoxia-induced chronic lung disease (CLD) in neonatal rats [11]. Moreover, the AT1
receptor-selective antagonists Candesartan [12] and Losartan [13,14] as well as the AT2
receptor-selective antagonist PD-123319 [15] were shown to have similar effects on
radiation-induced lung fibrosis and bleomycin-induced lung fibrosis in rats and mice. In
addition, ACE-2 overexpression by a lentiviral vector in the lung or systemic delivery of
purified ACE-2 attenuated bleomycin-induced pulmonary fibrosis in rats and mice [1,16].
Together, these results support the contention that ANGII plays an important role in lung
fibrogenesis via both AT1 and AT2 receptors.
Actions of Angiotensin on Lung Parenchymal Cells
The angiotensin system is known to be activated after tissue injury to promote tissue repair
and, when in excess, tissue fibrosis. ANGII, the major effector peptide of this system, is now
recognized as a growth factor that regulates cell growth and fibrogenesis. Previous works
from this laboratory have demonstrated the capacity for local (i.e., extravascular) ANGII
generation within the parenchyma of the lungs [17]. There is an increase of ANG peptides
and AT1 and AT 2 receptor expression in lung tissue from patients with IPF [17,18]. Lung
alveolar epithelial cells and myofibroblasts have been identified as the main local sources of
this angiotensin generation [17]. Here, we summarize the wide variety of ANGII functions
acting on lung parenchymal cells and discuss them in relation to the fibrotic cascade.
First, ANGII is mitogenic for human lung fibroblasts through AT1 and AT2 receptors [18].
The role of ANGII as a potent inducer of DNA synthesis and fibroblast proliferation has
been widely studied [19]. It has been shown (see Figure 1) that both AT1 and AT2 receptors
mediate ANGII signalling on fibroblast cell cycle and migration via phosphorylation of the
mitogen-activated protein kinases p38 and p42/44 [18,19]. Furthermore, the effect of ANGII
on human lung fibroblasts promotes extracellular matrix (ECM) synthesis [1,19]. Type I
collagen is a principal matrix protein in the lung interstitium. Excessive collagen type I,
mainly synthesized by activated fibroblasts, has been largely recognized in the pathogenesis
of fibrosis and causes thickened alveolar walls and reduction of lung compliance. It has been
demonstrated that ANGII signalling induces procollagen production in normal fibroblasts,
whereas AT1 receptor antagonists abrogate the constitutively higher collagen synthesis
exhibited by fibroblasts isolated from fibrotic human lung tissue [1]. ECM synthesis
mediated by ANGII has been ascribed not only to AT1 receptor activation but also to the
autocrine action of transforming growth factor-β1 (TGF-β1) [1,19] and connective tissue
growth factor (CTGF) [20]. Both growth factors contribute by themselves to the
development of lung fibrosis, in part by acting on human fibroblasts to enhance their
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differentiation to myofibroblasts and collagen synthesis. In vitro studies have demonstrated
that these pro-fibrotic effects induced by TGF-β1 and CTGF, as well as the collagen
synthesis triggered by oxidant stress, are abrogated through the blockade of angiotensin
receptors [1,19,21].
On the other hand, transcriptional regulation and autocrine loop systems are believed to be
involved in the molecular mechanisms by which ANGII exerts its functions in lung fibrosis.
For example, an ANGII-TGF-β1 crosstalk has been identified in lung fibroblasts isolated
from fibrotic human lung [1]. It has been demonstrated that the transition to the
myofibroblast phenotype induced by TGF-β1 results in an increase of AGT and AT1
receptor expression [1,22,23]. Recent data from our laboratory have shown that TGF-β1-
induced AGT expression is caused by an increased binding of two transcription factors
involved in the pathogenesis of lung fibrosis, JunD and hypoxia-inducible factor (HIF)-1α,
to an AGT promoter domain close to the transcription start site [23]. Earlier work revealed
that constitutive expression of active TGF-β1 by human lung myofibroblasts was
downregulated by ANGII receptor blockade and was accompanied by the inhibition of
collagen synthesis [1]. Therefore, local upregulation of either angiotensin or TGF-β1
expression could induce the other (i.e., an autocrine loop), and the synergy between both
systems should be inhibited in order to block the progression of lung fibrotic disease.
Recently Renzoni and coworkers [22] have described an additional effect of ANGII on ECM
and human lung fibroblast cells; they have observed that the increased contractility of lung
fibroblasts isolated from fibrotic lungs is dependent on angiotensin signalling. ANGII
stimulated the contraction of floating collagen gels and α-smooth muscle actin expression
by lung fibroblasts through activation of AT1 receptors. Consequently, in addition to
exerting the mitogenic and regulatory effects, ANGII can also modify cytoskeletal function
and the mechanical characteristics of human lung fibroblasts.
Little is known about the potential profibrotic actions of ANGII on other lung parenchymal
cells such as vascular cells or macrophages or mast cells, in part because these cells have not
yet been studied from the perspective of the local ANG system in the lungs, and also
because the function(s) of these cells in lung fibrosis is poorly understood.
Angiotensin Signalling in Alveolar Epithelial Cell Survival
Apoptosis of alveolar epithelial cells (AECs) is now believed to be a critical event in the
pathogenesis of pulmonary fibrosis. Support for this belief came first from animal models of
lung fibrosis, in which experimental inhibition of apoptosis by either caspase inhibition [7]
or deletion of genes necessary for epithelial apoptosis [24] decreased or abrogated the
fibrotic response subsequent to lung injury. On the other hand, experimental induction of
apoptosis primarily within AECs caused a subsequent fibrotic response, the severity of
which was proportional to the severity of apoptosis induction [25]. More recently, apoptosis
of AECs has become a consistent finding in biopsy specimens obtained from patients with
Idiopathic Pulmonary Fibrosis [1,18].
In a variety of organs including the liver, pancreas and lungs, ANGII is known to be
proapoptotic for epithelial cells [1]. In cultured lung AECs, ANGII induces apoptosis with
an EC50 of about 10nM [26]; similarly, ANGII induces apoptosis of cultured endothelial
cells with an EC50 of about 100nM [ibid]. These effective concentrations for apoptosis are
significantly higher than the steady-state concentration of ANGII within the circulation,
which rarely rises above 10pM, even in severe hypertension [1]; the higher levels of ANGII
required for apoptosis induction may explain how the ANGII generated by the action of
angiotensin converting enzyme (ACE) within the pulmonary vascular bed does not damage
the organ in which it is generated. On the other hand, measurements of steady-state ANGII
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concentrations in the extravascular compartment suggest that tissue ANGII levels are likely
orders of magnitude higher than those in the serum, due largely to the longer biological
halflife of ANGII outside the vasculature.
In addition, evidence suggests that at least two cell types in the lung, AECs and
myofibroblasts that emerge during wound healing, express ANGII de novo after lung injury.
In cultured AECs, exposure to chemical toxins such as bleomycin or endogenous toxins
such as Fas ligand or tumor necrosis factor (TNF)-alpha, all induce expression of AGT
mRNA, AGT protein and the mature octapeptide ANGII derived from it [1]. In addition, the
transition of normal lung fibroblasts to myofibroblasts upon exposure to TGF-β1 in vitro is
accompanied by robust expression of AGT mRNA, protein and ANGII peptide [23]. The
physiological relevance of these cell culture data is supported by the findings of AGT
mRNA and immunoreactive ANG peptides in apoptotic AECs and myofibroblasts within
lung sections obtained from bleomycin-injured rats [6] or biopsy specimens from patients
with IPF [17]. Thus, two additional sources of local production of ANGII, at concentrations
likely to be proapoptotic in the local microenvironment, are lung myofibroblasts and
apoptotic AECs themselves.
Apoptosis of AECs in response to ANGII is mediated by the AT1 receptor; ANGII-induced
cell loss and nuclear fragmentation in primary cultures of AECs could be blocked by the
AT1-selective antagonists L-158809 but not by the AT2-selective blocker PD126055 [26].
Subsequent studies found that the AT1 selective blockers L-158809 or Losartan could also
block bleomycin-induced nuclear fragmentation of cultured AECs; these data support the
premise that autocrine production of ANGII mediates the apoptotic response of AECs to
bleomycin [27]. When administered to mice, the AT1 blocker Losartan also significantly
reduced bleomycin-induced caspase 3 activation, which supports the theory that this
mechanism is also active in the intact lung in vivo.
The apoptotic response of AECs to AT1 receptor activation appears to be mediated by
protein kinase C (PKC, see Figure 2); the PKC inhibitor chelerythrine prevented ANGII-
mediated apoptosis measured by nuclear fragmentation assay in primary cultures of rat
alveolar epithelial cells [28]. Recent studies have shown that AECs also express angiotensin
converting enzyme-2 (ACE-2), the homolog of ACE that cleaves a single amino acid from
the c-terminal end of the octapeptide ANGII to form the heptapeptide ANG1-7 [1]. In
nonpulmonary cell types, ANG1-7 binds to the specific ANG1-7 receptor mas and inhibits
ANGII-induced activation of mitogen-activated protein kinases including JNK [4]. Lee et al.
[29] demonstrated that JNK phosphorylation is required for apoptosis of AECs; the specific
steps between PKC and p-JNK (?), if any, are currently unknown. Nonetheless, it was of
high interest to determine if ANG1-7 could also inhibit AT1-induced apoptosis of AECs
through the ANG1-7 receptor mas.
In recent studies published elsewhere [30] we found that ANG1-7 could inhibit JNK
phosphorylation in AECs exposed to either ANGII or bleomycin (Fig.2). ANG1-7 could
also inhibit AEC apoptosis stimulated by either of these inducers, as measured by caspase-3
or -9 activation or by nuclear fragmentation assay. Moreover, the inhibition by ANG1-7 was
exerted through the ANG1-7 receptor mas; this was shown by blockage of the inhibition
with the specific mas receptor blocker A779 or with antisense nucleotides against mas
mRNA [30]. The pathways by which activation of mas inhibits JNK phosphorylation (?? in
Fig.2), and therefore apoptosis of AECs, are currently under investigation. Our current
working hypothesis contends that activation of mas might induce a JNK phosphatase which,
under normal conditions in which ANG1-7 is much more abundant than ANGII (see 30),
constitutively dephosphorylates JNK as a cell survival mechanism. Evaluation of this
working hypothesis and identification of which, if any, JNK phosphatases might be
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activated by mas is currently under investigation in our laboratory. The cellular locations of
most of the event depicted in Figure 2 were drawn on the basis of the limited data currently
available, but may ultimately be found to occur in intra- or extracellular locations other than
those depicted.
Summary and Future Perspectives
A large body of literature has shown that angiotensin II (ANGII) stimulates expression of
TGF-β1 and α1 collagen by lung fibroblasts. In the human fibrotic lung, ANGII is
synthesized by lung myofibroblasts and dying lung epithelial cells. Cell culture and mouse
studies have shown that ANGII receptor AT1 mediates alveolar epithelial apoptosis through
JNK phosphorylation. Importantly, ANG1-7, the product of the counteregulatory enzyme
ACE-2 that degrades ANGII, inhibits JNK phosphorylation and apoptosis of lung epithelial
cells. Moreover, the specific ANG1-7 receptor mas mediates the antiapoptotic effects of
ANG1-7. These data offer new hypotheses regarding the potential of ANG1-7, or mimicks
of this peptide, in the control of apoptotic lung injury and fibrogenesis. Activators of mas or
other inhibitors of JNK phosphorylation would be expected to block both lung epithelial
apoptosis and the subsequent fibrotic response. Both these and related hypotheses will be
interesting topics for future inquiry.
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Known actions of angiotensin II on lung parenchymal cells. On lung fibroblasts, angiotensin
II (ANGII) has profibrotic actions on growth factor expression, extracellular matrix
synthesis and migration mediated through both AT1 and AT2 receptors. On lung vascular
smooth muscle (VSM) cells, ANGII promotes vasoconstriction, growth factor expression
and prostaglandin synthesis primarily through AT1 receptors. ANGII is proapoptotic for
alveolar lung epithelial cell (AECs). The functions of AT2 receptors on VSM and AECs, if
any, are currently unknown. See text for details and references.
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Known actions of angiotensin II on alveolar epithelial cell survival. The octapeptide
angiotensin (ANG)II induces apoptosis of alveolar epithelial cells (AECs) through the AT1
receptor; the protein kinase C (PKC) inhibitor chelerythrine blocked AEC apoptosis in
response to ANGII. Moreover, the phosphorylation of JUN N-terminal Kinase (p-JNK) is a
required event in AEC apoptosis in response to ANGII or bleomycin. Angiotensin
converting enzyme-2 (ACE-2) acts as a survival factor by a) degrading the proapoptotic
ANGII and b) producing the heptapeptide angiotensin1-7 (ANG1-7), which inhibits
apoptosis by blocking JNK phosphorylation through the ANG1-7 receptor mas. Both JNK
phosphorylation and apoptosis of AECs can be blocked by either the specific mas receptor
antagonist A779 (D-Ala7-Ang1–7) or by antisense oligonucleotides against mas mRNA
(masAS). The steps, if any, between PKC and p-JNK (?) are currently unknown. Similarly,
the mechanism(s) by which mas activation inhibits JNK phosphorylation (??) in AECs are
unknown but are currently being investigated. The intra-versus extracellular locations of
each of the events described are currently unknown, but were depicted as shown on the basis
of available data; whether ANGII accumulation, degradation to ANG1-7 and/or binding to
AT1 or mas can occur intracellularly is presently unknown. See text for more detail.
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